<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171611</url>
  </required_header>
  <id_info>
    <org_study_id>1160.87</org_study_id>
    <nct_id>NCT02171611</nct_id>
  </id_info>
  <brief_title>Bioavailability of Different Applications of Dabigatran in Healthy Volunteers</brief_title>
  <official_title>Relative Bioavailability of Dabigatran After Administration of Different Application Forms of a Single Oral Dose of 150 mg Dabigatran Etexilate (Capsule, Powder for Reconstitution Into Solution, Pellets on Food) in Healthy Male and Female Volunteers (an Open-label, Randomised, Three-way Crossover, Clinical Phase I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To determine the relative bioavailability of 150 mg of dabigatran etexilate as pellets on
      food and of 150 mg of dabigatran etexilate as powder resolved in reconstitution solution,
      both with 150 mg of dabigatran etexilate as capsule in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-inf for Total Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) for total dabigatran.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf for Free Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) for free dabigatran.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Total Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
    <description>Maximum measured concentration of the analyte in plasma (Cmax) for total dabigatran.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Free Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
    <description>Maximum measured concentration of the analyte in plasma (Cmax) for free dabigatran</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz for Total Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz) for total dabigatran.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz for Free Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz) for free dabigatran.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for Total Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
    <description>Time from dosing to the maximum concentration of the analyte in plasma (tmax) for total dabigatran</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for Free Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
    <description>Time from dosing to the maximum concentration of the analyte in plasma (tmax) for free dabigatran</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz for Total Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
    <description>Terminal rate constant in plasma (λz) for total dabigatran.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz for Free Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 for Total Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
    <description>Terminal half-life of the analyte in plasma (t1/2) for total dabigatran</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 for Free Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
    <description>Terminal half-life of the analyte in plasma (t1/2) for free dabigatran.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo for Total Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
    <description>Mean residence time of the analyte in the body after po administration (MRTpo) for total dabigatran.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo for Free Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
    <description>Mean residence time of the analyte in the body after po administration (MRTpo) for free dabigatran.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for Total Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
    <description>Apparent clearance of the analyte in plasma following extravascular administration (CL/F) for total dabigatran.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for Free Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
    <description>Apparent clearance of the analyte in plasma following extravascular administration (CL/F) for free dabigatran.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F for Total Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
    <description>Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F) for total dabigatran.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F for Free Dabigatran</measure>
    <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
    <description>Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F) for free dabigatran.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Findings in Physical Examination, Vital Signs , Pulse Rate (PR)), 12-lead ECG, Clinical Laboratory Tests.</measure>
    <time_frame>From first drug administration until 7 days after the last drug administration of Dabigatran, ie., up to 10 days.</time_frame>
    <description>Percentage of participants with findings in Physical examination, Vital signs (blood pressure (BP), pulse rate (PR)), 12-lead ECG (electrocardiogram), Clinical laboratory tests (haematology, clinical chemistry and urinalysis). Relevant findings or worsening of baseline conditions were reported as Adverse events.
There were no clinically relevant finding reported for Physical examination, Vital signs (blood pressure, pulse rate), 12-lead ECG and Clinical laboratory tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Drug-related Adverse Events</measure>
    <time_frame>From first drug administration until 7 days after the last drug administration of Dabigatran, ie., up to 10 days.</time_frame>
    <description>Percentage of participants with investigator defined drug−releated Adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Tolerability by Investigator.</measure>
    <time_frame>From first drug administration until 7 days after the last drug administration of Dabigatran, ie., up to 10 days.</time_frame>
    <description>Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory and bad.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate pellets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate pellets</intervention_name>
    <arm_group_label>Dabigatran etexilate pellets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate powder</intervention_name>
    <arm_group_label>Dabigatran etexilate powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate capsule</intervention_name>
    <arm_group_label>Dabigatran etexilate capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females according to the following criteria: Based upon a complete
             medical history, including the physical examination, vital signs (BP, PR), 12-lead
             ECG, clinical laboratory tests

          -  Age ≥18 and age ≤50 years

          -  BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation

        Exclusion Criteria:

          -  Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance

          -  Any evidence of a clinically relevant concomitant disease

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Surgery of the gastrointestinal tract (except appendectomy)

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  History of relevant orthostatic hypotension, fainting spells or blackouts

          -  Chronic or relevant acute infections

          -  History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          -  Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

          -  Use of drugs which could reasonably influence the results of the trial (especially
             unspecific inducing agents like St. John´s wort (Hypericum perforatum) or that prolong
             the QT/QTc interval based on the knowledge at the time of protocol preparation within
             10 days prior to administration or during the trial

          -  Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

          -  Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)

          -  Inability to refrain from smoking on trial days

          -  Alcohol abuse (more than 60 g/day)

          -  Drug abuse

          -  Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

          -  Excessive physical activities (within one week prior to administration or during the
             trial)

          -  Any laboratory value outside the reference range that was of clinical relevance

          -  Inability to comply with dietary regimen of trial site

          -  A marked baseline prolongation of QT/QTc interval (e.g. repeated demonstration of a
             QTc interval &gt;450 ms)

          -  A history of additional risk factors for Torsade de Pointes (e.g. heart failure,
             hypokalemia, family history of Long QT Syndrome)

          -  For female subjects:

               -  Positive pregnancy test, pregnancy or planning to become pregnant during the
                  study or within 1 month after study completion

               -  No adequate contraception during the study and until 1 month after study
                  completion, i.e. not any of the following: implants, injectables, combined oral
                  contraceptives, intrauterine device (IUD), sexual abstinence for at least 1 month
                  prior to enrolment, vasectomised partner (vasectomy performed at least 1 year
                  prior to enrolment), or surgical sterilisation (including hysterectomy). Females,
                  who did not have a vasectomised partner, were not sexually abstinent or
                  surgically sterile were to be asked to use an additional barrier method (e.g.
                  condom, diaphragm with spermicide)

               -  Lactation

          -  Intake of medication, which influences the blood clotting, i.e. acetylsalicylic acid,
             oral vitamin K antagonists etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <results_first_submitted>March 15, 2017</results_first_submitted>
  <results_first_submitted_qc>March 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2017</results_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>A/B/C</title>
          <description>Subjects were treated after an overnight fast of at least 10 hours with single oral dose, started in Period 1 with Dabigatran etexilate 150 mg capsule: Reference (A) with about 240 mL of water and in Period 2 with Dabigatran etexilate 150 mg pellets: Test 1 (B) by sprinkling the pellets on a teaspoon of food and administered immediately to the subject, followed in period 3 with Dabigatran etexilate 150 mg powder: Test 2 (C) resolved in 24 mL reconstitution solution.
Treatments were separated by washout period of at least 7 days after drug administration.</description>
        </group>
        <group group_id="P2">
          <title>A/C/B</title>
          <description>Subjects were treated after an overnight fast of at least 10 hours with single oral dose, started in Period 1 with Dabigatran etexilate 150 mg capsule: Reference (A) with about 240 mL of water and in period 2 with Dabigatran etexilate 150 mg powder: Test 2 (C) resolved in 24 mL reconstitution solution, followed in Period 3 with Dabigatran etexilate 150 mg pellets: Test 1 (B) by sprinkling the pellets on a teaspoon of food and administered immediately to the subject.
Treatments were separated by washout period of at least 7 days after drug administration.</description>
        </group>
        <group group_id="P3">
          <title>B/A/C</title>
          <description>Subjects were treated after an overnight fast of at least 10 hours with single oral dose, started in Period 1 with Dabigatran etexilate 150 mg pellets: Test 1 (B) by sprinkling the pellets on a teaspoon of food and administered immediately to the subject and in period 2 with Dabigatran etexilate 150 mg capsule: Reference (A) with about 240 mL of water, followed in Period 3 with Dabigatran etexilate 150 mg powder: Test 2 (C) resolved in 24 mL reconstitution solution.
Treatments were separated by washout period of at least 7 days after drug administration.</description>
        </group>
        <group group_id="P4">
          <title>B/C/A</title>
          <description>Subjects were treated after an overnight fast of at least 10 hours with single oral dose, started in Period 1 with Dabigatran etexilate 150 mg pellets: Test 1 (B) by sprinkling the pellets on a teaspoon of food and administered immediately to the subject and in period 2 with Dabigatran etexilate 150 mg powder: Test 2 (C) resolved in 24 mL reconstitution solution, followed in period 3 with Dabigatran etexilate 150 mg capsule: Reference (A) with about 240 mL of water.
Treatments were separated by washout period of at least 7 days after drug administration.</description>
        </group>
        <group group_id="P5">
          <title>C/A/B</title>
          <description>Subjects were treated after an overnight fast of at least 10 hours with single oral dose, started in Period 1 with Dabigatran etexilate 150 mg powder: Test 2 (C) resolved in 24 mL reconstitution solution and in period 2 with Dabigatran etexilate 150 mg capsule: Reference (A) with about 240 mL of water, followed in Period 3 with Dabigatran etexilate 150 mg pellets: Test 1 (B) by sprinkling the pellets on a teaspoon of food and administered immediately to the subject. Treatments were separated by washout period of at least 7 days after drug administration.</description>
        </group>
        <group group_id="P6">
          <title>C/B/A</title>
          <description>Subjects were treated after an overnight fast of at least 10 hours with single oral dose, started in Period 1 with Dabigatran etexilate 150 mg powder: Test 2 (C) resolved in 24 mL reconstitution solution and in period 2 with Dabigatran etexilate 150 mg pellets: Test 1 (B) by sprinkling the pellets on a teaspoon of food and administered immediately to the subject, followed in Period 3 with Dabigatran etexilate 150 mg capsule: Reference (A) with about 240 mL of water.
Treatments were separated by washout period of at least 7 days after drug administration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS): This subject set included all subjects who were dispensed trial medication and were documented to have taken at least one dose of investigational treatment. This set was used for safety analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>This study is open-label, single dose, randomised, three-way crossover design having 3 treatment periods ie., Dabigatran etexilate 150 mg formulation capsule: Reference (A), Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) and Dabigatran etexilate 150 mg formulation powder: Test 2 (C)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.8" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf for Total Dabigatran</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) for total dabigatran.</description>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>PK-Per protocol set (PK-PPS): This subject set included all subjects in the treated set who provided at least one observation for at least one primary (PK) endpoint without important protocol violations with respect to the evaluation of relative bioavailability and who did not vomit at or before 2 times the median tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf for Total Dabigatran</title>
          <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) for total dabigatran.</description>
          <population>PK-Per protocol set (PK-PPS): This subject set included all subjects in the treated set who provided at least one observation for at least one primary (PK) endpoint without important protocol violations with respect to the evaluation of relative bioavailability and who did not vomit at or before 2 times the median tmax.</population>
          <units>ng(nanogram)*h(hour)/mL(milliliter)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="599" spread="93.3"/>
                    <measurement group_id="O2" value="1050" spread="33.8"/>
                    <measurement group_id="O3" value="928" spread="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An Analysis of variance (ANOVA) model was used on the logarithmic scale in order to compare the Test treatment vs. the Reference treatment. This model included effects for 'sequence', 'subjects within sequences', 'period' and 'treatment'. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>175.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>50.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>141.904</ci_lower_limit>
            <ci_upper_limit>216.149</ci_upper_limit>
            <estimate_desc>Relative bioavailability was estimated by the ratio of the gMeans of Dabigatran etexilate 150 mg (T1) divided by Dabigatran etexilate 150 mg (R). Standard Error of the mean is actually the intra individual coefficient variation (gCV).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>An Analysis of variance (ANOVA) model was used on the logarithmic scale in order to compare the Test treatment (T2) vs. the Reference treatment (R). This model included effects for 'sequence', 'subjects within sequences', 'period' and 'treatment'. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>154.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>46.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>127.425</ci_lower_limit>
            <ci_upper_limit>188.161</ci_upper_limit>
            <estimate_desc>Relative bioavailability was estimated by the ratio of the geometric means (gMeans) of Dabigatran etexilate 150 mg (T2) divided by Dabigatran etexilate 150 mg (R). Standard Error of the mean is actually the intra individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf for Free Dabigatran</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) for free dabigatran.</description>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>pharmacokinetic per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf for Free Dabigatran</title>
          <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) for free dabigatran.</description>
          <population>pharmacokinetic per-protocol set</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="464" spread="97.3"/>
                    <measurement group_id="O2" value="815" spread="40"/>
                    <measurement group_id="O3" value="734" spread="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An Analysis of variance (ANOVA) model was used on the logarithmic scale in order to compare the Test treatment vs. the Reference treatment. This model included effects for 'sequence', 'subjects within sequences', 'period' and 'treatment'. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means in %</param_type>
            <param_value>175.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>51.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>141.924</ci_lower_limit>
            <ci_upper_limit>216.772</ci_upper_limit>
            <estimate_desc>Relative bioavailability was estimated by the ratio of the gMean of Dabigatran etexilate 150 mg (T1) divided by Dabigatran etexilate 150 mg (R). Standard Error of the mean is actually the intra individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>An Analysis of variance (ANOVA) model was used on the logarithmic scale in order to compare the Test treatment vs. the Reference treatment. This model included effects for 'sequence', 'subjects within sequences', 'period' and 'treatment'. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means in %</param_type>
            <param_value>158.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>46.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>130.052</ci_lower_limit>
            <ci_upper_limit>192.255</ci_upper_limit>
            <estimate_desc>Relative bioavailability was estimated by the ratio of the gMean of Dabigatran etexilate 150 mg (T2) divided by Dabigatran etexilate 150 mg (R). Standard Error of the mean is actually the intra individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Total Dabigatran</title>
        <description>Maximum measured concentration of the analyte in plasma (Cmax) for total dabigatran.</description>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>pharmacokinetic per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Total Dabigatran</title>
          <description>Maximum measured concentration of the analyte in plasma (Cmax) for total dabigatran.</description>
          <population>pharmacokinetic per-protocol set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" spread="110"/>
                    <measurement group_id="O2" value="139" spread="37.8"/>
                    <measurement group_id="O3" value="124" spread="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An Analysis of variance (ANOVA) model was used on the logarithmic scale in order to compare the Test treatment vs. the Reference treatment. This model included effects for 'sequence', 'subjects within sequences', 'period' and 'treatment'. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>186.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>57.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>147.659</ci_lower_limit>
            <ci_upper_limit>236.665</ci_upper_limit>
            <estimate_desc>Relative bioavailability was estimated by the ratio of the gMean of Dabigatran etexilate 150 mg (T1) divided by Dabigatran etexilate 150 mg (R). Standard Error of the mean is actually the intra individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>An Analysis of variance (ANOVA) model was used on the logarithmic scale in order to compare the Test treatment vs. the Reference treatment. This model included effects for 'sequence', 'subjects within sequences', 'period' and 'treatment'. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means in %</param_type>
            <param_value>166.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>54.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>133.221</ci_lower_limit>
            <ci_upper_limit>208.326</ci_upper_limit>
            <estimate_desc>Relative bioavailability was estimated by the ratio of the gMean of Dabigatran etexilate 150 mg (T2) divided by Dabigatran etexilate 150 mg (R). Standard Error of the mean is actually the intra individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Free Dabigatran</title>
        <description>Maximum measured concentration of the analyte in plasma (Cmax) for free dabigatran</description>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>pharmacokinetic per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Free Dabigatran</title>
          <description>Maximum measured concentration of the analyte in plasma (Cmax) for free dabigatran</description>
          <population>pharmacokinetic per-protocol set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" spread="110"/>
                    <measurement group_id="O2" value="112" spread="40.4"/>
                    <measurement group_id="O3" value="103" spread="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An Analysis of variance (ANOVA) model was used on the logarithmic scale in order to compare the Test treatment vs. the Reference treatment. This model included effects for 'sequence', 'subjects within sequences', 'period' and 'treatment'. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means in %</param_type>
            <param_value>181.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>53.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>145.428</ci_lower_limit>
            <ci_upper_limit>226.776</ci_upper_limit>
            <estimate_desc>Relative bioavailability was estimated by the ratio of the gMean of Dabigatran etexilate 150 mg (T1) divided by Dabigatran etexilate 150 mg (R). Standard Error of the mean is actually the intra individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>An Analysis of variance (ANOVA) model was used on the logarithmic scale in order to compare the Test treatment vs. the Reference treatment. This model included effects for 'sequence', 'subjects within sequences', 'period' and 'treatment'. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means in %</param_type>
            <param_value>166.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>52.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>134.25</ci_lower_limit>
            <ci_upper_limit>207.328</ci_upper_limit>
            <estimate_desc>Relative bioavailability was estimated by the ratio of the gMean of Dabigatran etexilate 150 mg (T2) divided by Dabigatran etexilate 150 mg (R). Standard Error of the mean is actually the intra individual geometric coefficient variation (gCV).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-tz for Total Dabigatran</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz) for total dabigatran.</description>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>pharmacokinetic per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-tz for Total Dabigatran</title>
          <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz) for total dabigatran.</description>
          <population>pharmacokinetic per-protocol set</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="565" spread="106"/>
                    <measurement group_id="O2" value="1030" spread="34.2"/>
                    <measurement group_id="O3" value="908" spread="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An Analysis of variance (ANOVA) model was used on the logarithmic scale in order to compare the Test treatment vs. the Reference treatment. This model included effects for 'sequence', 'subjects within sequences', 'period' and 'treatment'. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means in %</param_type>
            <param_value>182.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>56.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>144.727</ci_lower_limit>
            <ci_upper_limit>229.297</ci_upper_limit>
            <estimate_desc>Relative bioavailability was estimated by the ratio of the gMean of Dabigatran etexilate 150 mg (T1) divided by Dabigatran etexilate 150 mg (R). Standard Error of the mean is actually the intra individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>An Analysis of variance (ANOVA) model was used on the logarithmic scale in order to compare the Test treatment vs. the Reference treatment. This model included effects for 'sequence', 'subjects within sequences', 'period' and 'treatment'. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means in %</param_type>
            <param_value>160.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>52</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>129.633</ci_lower_limit>
            <ci_upper_limit>199.306</ci_upper_limit>
            <estimate_desc>Relative bioavailability was estimated by the ratio of the gMean of Dabigatran etexilate 150 mg (T2) divided by Dabigatran etexilate 150 mg (R). Standard Error of the mean is actually the intra individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-tz for Free Dabigatran</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz) for free dabigatran.</description>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>pharmacokinetic per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-tz for Free Dabigatran</title>
          <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz) for free dabigatran.</description>
          <population>pharmacokinetic per-protocol set</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436" spread="110"/>
                    <measurement group_id="O2" value="794" spread="41.3"/>
                    <measurement group_id="O3" value="715" spread="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An Analysis of variance (ANOVA) model was used on the logarithmic scale in order to compare the Test treatment vs. the Reference treatment. This model included effects for 'sequence', 'subjects within sequences', 'period' and 'treatment'. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means in %</param_type>
            <param_value>182.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>55.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>144.993</ci_lower_limit>
            <ci_upper_limit>229.075</ci_upper_limit>
            <estimate_desc>Relative bioavailability was estimated by the ratio of the gMean of Dabigatran etexilate 150 mg (T1) divided by Dabigatran etexilate 150 mg (R). Standard Error of the mean is actually the intra individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>An Analysis of variance (ANOVA) model was used on the logarithmic scale in order to compare the Test treatment vs. the Reference treatment. This model included effects for 'sequence', 'subjects within sequences', 'period' and 'treatment'. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means in %</param_type>
            <param_value>164.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>51.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>132.421</ci_lower_limit>
            <ci_upper_limit>203.14</ci_upper_limit>
            <estimate_desc>Relative bioavailability was estimated by the ratio of the gMean of Dabigatran etexilate 150 mg (T2) divided by Dabigatran etexilate 150 mg (R). Standard Error of the mean is actually the intra individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax for Total Dabigatran</title>
        <description>Time from dosing to the maximum concentration of the analyte in plasma (tmax) for total dabigatran</description>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>pharmacokinetic per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax for Total Dabigatran</title>
          <description>Time from dosing to the maximum concentration of the analyte in plasma (tmax) for total dabigatran</description>
          <population>pharmacokinetic per-protocol set</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.5" upper_limit="6.0"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.0" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax for Free Dabigatran</title>
        <description>Time from dosing to the maximum concentration of the analyte in plasma (tmax) for free dabigatran</description>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>pharmacokinetic per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax for Free Dabigatran</title>
          <description>Time from dosing to the maximum concentration of the analyte in plasma (tmax) for free dabigatran</description>
          <population>pharmacokinetic per-protocol set</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.5" upper_limit="6.0"/>
                    <measurement group_id="O2" value="1.51" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>λz for Total Dabigatran</title>
        <description>Terminal rate constant in plasma (λz) for total dabigatran.</description>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>pharmacokinetic per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>λz for Total Dabigatran</title>
          <description>Terminal rate constant in plasma (λz) for total dabigatran.</description>
          <population>pharmacokinetic per-protocol set</population>
          <units>1/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.079" spread="13.5"/>
                    <measurement group_id="O2" value="0.074" spread="14.5"/>
                    <measurement group_id="O3" value="0.0756" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>λz for Free Dabigatran</title>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>pharmacokinetic per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>λz for Free Dabigatran</title>
          <population>pharmacokinetic per-protocol set</population>
          <units>1/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.091" spread="16"/>
                    <measurement group_id="O2" value="0.0811" spread="18.6"/>
                    <measurement group_id="O3" value="0.0893" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2 for Total Dabigatran</title>
        <description>Terminal half-life of the analyte in plasma (t1/2) for total dabigatran</description>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>pharmacokinetic per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 for Total Dabigatran</title>
          <description>Terminal half-life of the analyte in plasma (t1/2) for total dabigatran</description>
          <population>pharmacokinetic per-protocol set</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.77" spread="13.5"/>
                    <measurement group_id="O2" value="9.37" spread="14.5"/>
                    <measurement group_id="O3" value="9.16" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2 for Free Dabigatran</title>
        <description>Terminal half-life of the analyte in plasma (t1/2) for free dabigatran.</description>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>pharmacokinetic per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 for Free Dabigatran</title>
          <description>Terminal half-life of the analyte in plasma (t1/2) for free dabigatran.</description>
          <population>pharmacokinetic per-protocol set</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.62" spread="16"/>
                    <measurement group_id="O2" value="8.54" spread="18.6"/>
                    <measurement group_id="O3" value="7.76" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRTpo for Total Dabigatran</title>
        <description>Mean residence time of the analyte in the body after po administration (MRTpo) for total dabigatran.</description>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>pharmacokinetic per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>MRTpo for Total Dabigatran</title>
          <description>Mean residence time of the analyte in the body after po administration (MRTpo) for total dabigatran.</description>
          <population>pharmacokinetic per-protocol set</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="12"/>
                    <measurement group_id="O2" value="10.1" spread="11.4"/>
                    <measurement group_id="O3" value="10" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRTpo for Free Dabigatran</title>
        <description>Mean residence time of the analyte in the body after po administration (MRTpo) for free dabigatran.</description>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>pharmacokinetic per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>MRTpo for Free Dabigatran</title>
          <description>Mean residence time of the analyte in the body after po administration (MRTpo) for free dabigatran.</description>
          <population>pharmacokinetic per-protocol set</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="14.0"/>
                    <measurement group_id="O2" value="9.58" spread="14.1"/>
                    <measurement group_id="O3" value="9.15" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F for Total Dabigatran</title>
        <description>Apparent clearance of the analyte in plasma following extravascular administration (CL/F) for total dabigatran.</description>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>pharmacokinetic per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F for Total Dabigatran</title>
          <description>Apparent clearance of the analyte in plasma following extravascular administration (CL/F) for total dabigatran.</description>
          <population>pharmacokinetic per-protocol set</population>
          <units>mL (milliliter)/min (minute)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3130" spread="93.3"/>
                    <measurement group_id="O2" value="1790" spread="33.8"/>
                    <measurement group_id="O3" value="2020" spread="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F for Free Dabigatran</title>
        <description>Apparent clearance of the analyte in plasma following extravascular administration (CL/F) for free dabigatran.</description>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>pharmacokinetic per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F for Free Dabigatran</title>
          <description>Apparent clearance of the analyte in plasma following extravascular administration (CL/F) for free dabigatran.</description>
          <population>pharmacokinetic per-protocol set</population>
          <units>mL (milliliter)/min (minute)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4040" spread="97.3"/>
                    <measurement group_id="O2" value="2310" spread="40"/>
                    <measurement group_id="O3" value="2560" spread="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vz/F for Total Dabigatran</title>
        <description>Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F) for total dabigatran.</description>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>pharmacokinetic per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Vz/F for Total Dabigatran</title>
          <description>Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F) for total dabigatran.</description>
          <population>pharmacokinetic per-protocol set</population>
          <units>Liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2380" spread="92.8"/>
                    <measurement group_id="O2" value="1450" spread="35"/>
                    <measurement group_id="O3" value="1610" spread="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vz/F for Free Dabigatran</title>
        <description>Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F) for free dabigatran.</description>
        <time_frame>-0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.</time_frame>
        <population>pharmacokinetic per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Vz/F for Free Dabigatran</title>
          <description>Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F) for free dabigatran.</description>
          <population>pharmacokinetic per-protocol set</population>
          <units>Liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2670" spread="91"/>
                    <measurement group_id="O2" value="1700" spread="41.4"/>
                    <measurement group_id="O3" value="1720" spread="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Findings in Physical Examination, Vital Signs , Pulse Rate (PR)), 12-lead ECG, Clinical Laboratory Tests.</title>
        <description>Percentage of participants with findings in Physical examination, Vital signs (blood pressure (BP), pulse rate (PR)), 12-lead ECG (electrocardiogram), Clinical laboratory tests (haematology, clinical chemistry and urinalysis). Relevant findings or worsening of baseline conditions were reported as Adverse events.
There were no clinically relevant finding reported for Physical examination, Vital signs (blood pressure, pulse rate), 12-lead ECG and Clinical laboratory tests.</description>
        <time_frame>From first drug administration until 7 days after the last drug administration of Dabigatran, ie., up to 10 days.</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Findings in Physical Examination, Vital Signs , Pulse Rate (PR)), 12-lead ECG, Clinical Laboratory Tests.</title>
          <description>Percentage of participants with findings in Physical examination, Vital signs (blood pressure (BP), pulse rate (PR)), 12-lead ECG (electrocardiogram), Clinical laboratory tests (haematology, clinical chemistry and urinalysis). Relevant findings or worsening of baseline conditions were reported as Adverse events.
There were no clinically relevant finding reported for Physical examination, Vital signs (blood pressure, pulse rate), 12-lead ECG and Clinical laboratory tests.</description>
          <population>Treated Set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Drug-related Adverse Events</title>
        <description>Percentage of participants with investigator defined drug−releated Adverse events.</description>
        <time_frame>From first drug administration until 7 days after the last drug administration of Dabigatran, ie., up to 10 days.</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Drug-related Adverse Events</title>
          <description>Percentage of participants with investigator defined drug−releated Adverse events.</description>
          <population>Treated set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="23.3"/>
                    <measurement group_id="O3" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Tolerability by Investigator.</title>
        <description>Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory and bad.</description>
        <time_frame>From first drug administration until 7 days after the last drug administration of Dabigatran, ie., up to 10 days.</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
            <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Tolerability by Investigator.</title>
          <description>Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory and bad.</description>
          <population>Treated Set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bad</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not assessable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 7 days after the last drug administration of Dabigatran, ie., up to 10 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran Etexilate 150 mg Capsule: Reference (A)</title>
          <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation capsule: Reference (A) after an overnight fast of at least 10 hours with about 240 milliliter (mL) of water.</description>
        </group>
        <group group_id="E2">
          <title>Dabigatran Etexilate 150 mg Pellets: Test 1 (B)</title>
          <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation pellets: Test 1 (B) after an overnight fast of at least 10 hours. Pellets were sprinkled on a teaspoon of food and administered immediately to the subject.</description>
        </group>
        <group group_id="E3">
          <title>Dabigatran Etexilate 150 mg Powder: Test 2 (C)</title>
          <description>Subjects were treated with single oral dose of Dabigatran etexilate 150 mg formulation powder: Test 2 (C) resolved in 24 mL reconstitution solution after an overnight fast of at least 10 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

